Praxis Precision Medicines Inc (PRAX) reported a third-quarter loss of $3.36 per share for fiscal 2025, surpassing Wall Street's consensus estimate of $3.51. Revenue remained at $0.0 billion, consistent with analyst expectations.
The company's performance highlights its operational resilience in the biotechnology sector, which focuses on developing therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. Praxis employs genetic insights through its two platforms: Cerebrum, a small-molecule platform, and Solidus, an antisense oligonucleotide platform.
The firm will host an earnings conference call at 8:00 AM EST to discuss these results and provide additional insights into its business performance. Investors are encouraged to review the full earnings release and listen to management commentary for comprehensive context on the quarter's performance and future outlook.
As of November 8, 2025, Praxis Precision Medicines has a market capitalization of $4.21 billion and a trailing twelve-month EPS of $-12.29. The company is scheduled to report its next earnings on August 2, 2026, with an estimated EPS of $-3.1994 and revenue expected to remain at $0.0 billion.